How can we better protect children from malaria in highly seasonal regions?
Epicentre is pleased to be part of the Imvacs Project testing an integrated approach: combining the R21/Matrix-M vaccine with Seasonal Malaria Chemoprevention for children in Mali & Burkina Faso.
youtu.be/r2v9EvWQ1JE?...

In Mali, an ancillary study compares two R21/Matrix-M vaccine formulation —10-dose vs. 2-dose—to simplify logistics, as part of the broader #IMVACS project which aims to evaluate the effectiveness of a new integrated strategy for administering this vaccine.
www.imvacs.org/safli-r21-10/

🦟 From #Mali’s success to #BurkinaFaso’s, our #IMVACS project is moving forward on the #malaria vaccination campaign.

The IMVACs project will build multidisciplinary evidence to support integrating the malaria vaccine with seasonal malaria chemoprevention in West Africa.

Great to see the IMVACS malaria vaccine trial advancing in Mali!
Epicentre is proud to be part of this important study with local research teams in Mali and Burkina Faso to identify the most effective strategy to protect young children from malaria. www.imvacs.org/official-sta...

🚀 Proud to be part of the IMVACS Consortium, working on an integrated delivery strategy for the R21/Matrix-M Malaria #vaccine! 💉
The recent advances in malaria vaccination bring new hope, but ensuring equitable access and effective delivery is now the key challenge.

www.imvacs.org/imvacs-kick-...

We are looking for a coordinator for the IMVACS study comparing 2 strategies for dispensing the R21/Matrix-M vaccine in Mali and Burkina Faso. This position is based in Niamey, Niger.
If you have a Masters or PhD in Public Health and/or Epidemiology, apply here👇
smrtr.io/pkPZ3

Hammersmith: EGFRi decreases PD-L1 expression ... May impact how we sequence combinations with immunotherapeutics #imvacs #oncology

Hammersmith: how do canonical signaling pathway mutations alter expression of immune checkpoint genes? Time to look! #imvacs

Hammersmith; HLA-A LOF frequently seen in lung squamous cell carcinoma, among other immune related genes (TCGA 2012) #ImVacS

Hammersmith: Skeptical genomicist have been proven wrong about value of immunotherapy initially thought "too complex" #ImVacS

Peter Hammersmith speaking at #ImVacS on convergence between canonical signaling (RAS, PI3K) and immuno-oncology. #oncology #singularity

Main takehome points of #ImVacS today: Tim-3, Tim-3, Tim-3, and combinations, combinations, combinations. #immunotherapy #oncology

While his point may be salient it is no excuse to be rude to the speaker. He should kvetch to the #imvacs organizers and @CHI_Healthtech

At #ImVacS and just heard an academic speaker call out an industry speaker about not disclosing his companies new preclinical targets (1/2)

Looking forward to being in Boston next week for ImVacS: The Immunotherapies and Vaccine Summit http://goo.gl/fb/O6edCF”